Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 4;6(11):1361-80.
doi: 10.3390/ph6111361.

Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes

Mónica Rivera Díaz  1 , Pablo E Vivas-Mejia
Affiliations

Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes

Mónica Rivera Díaz et al. Pharmaceuticals (Basel). .

Abstract

Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nanoliposomes for drug delivery.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012;63:185–198. doi: 10.1146/annurev-med-040210-162544. - DOI - PubMed
    1. Chaudhary U.B., Haldas J.R. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003;63:1565–1577. doi: 10.2165/00003495-200363150-00004. - DOI - PubMed
    1. Lipshultz S.E., Lipsitz S.R., Mone S.M., Goorin A.M., Sallan S.E., Sanders S.P., Orav E.J., Gelber R.D., Colan S.D. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 1995;332:1738–1743. doi: 10.1056/NEJM199506293322602. - DOI - PubMed
    1. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392. - PubMed
    1. Ochekpe N.A., Olorunfemi P.O., Ngwuluka N. Nanotechnology and Drug Delivery Part 1: Background and Applications. Trop. J. Pharm. Res. 2009;8:265–274.